At the American Academy of Ophthalmology meeting, NeoVista made public the one-year results from their MERITAGE Study. This study was designed to examine NeoVista’s Epimacular Brachytherapy procedure when used in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Neovascular Age-Related Macular Degeneration (Wet AMD).

Study results to date suggest that a single procedure of Epimacular Brachytherapy can stabilize visual acuity in a majority of wet AMD patients (79%) while decreasing the number of anti-VEGF injections required. Most
importantly, 47% of patients enrolled in the study experienced some improvement in their visual acuity while 10% of patients gained 15 or more letters of visual acuity at 12 months. This improvement is significant in patients that had been receiving chronic anti-VEGF treatment with no vision improvement in the year prior to enrollment.

Read ^[1] the full release.